CHICAGO (MedPage Today) — Although most preterm babies with retinopathy of prematurity (ROP) can have their sight saved if the condition is detected promptly, that fails to happen in far too many cases, a researcher charges in this exclusive InFocus r…
ISTA Pharmaceuticals Receives FDA Approval For BROMDAY™
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for BROMDAY™ (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye …
Some Retinitis Pigmentosa Patients May Benefit From Beta Carotene
Today’s Scientific Program of the 2010 American Academy of Ophthalmology (AAO) – Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting includes a report on beta carotene’s ability to improve vision in people with certain incurable retinal d…
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE 2)
Status: Recruiting,
Condition Summary: Ischemia; Retinal Vein Occlusion; Pathologic Processes; Retinal Diseases; Eye Diseases
Bromday Eye Drops (Bromfenac Ophthalmic Solution) Approved For Post-operative Inflammation
Patients with post-operative eye inflammation as well as those who have undergone cataract surgery and experience eye pain may be considered for Bromday once-daily eye-drop treatment, as it was approved for both indications by the FDA (Food and Drug Ad…
AAO: Retinoid Drug May Slow Dry AMD Progression (CME/CE)
CHICAGO (MedPage Today) — Fenretinide could still become the first disease-modifying treatment for geographic atrophy — the end stage of “dry” age-related macular degeneration (AMD) — in spite of a bungled phase II trial, researchers said here.